A uniquely defensible, recurring-revenue oncology platform hits a major pancreatic cancer inflection—yet near-term CMS billing disruption and execution risk keep valuation depressed.
Overview
Novocure (NVCR) is an oncology-focused med-tech company built around Tumor Treating Fields (TTFields), a non-invasive, wearable therapy that uses tuned alternating electric fields (generally 100–500 kHz) to disrupt cancer cell division by interfering with mitotic protein alignment, driving mitotic catastrophe while largely sparing non-dividing healthy tissue. Its commercial systems include **Optune Gio** for glioblastoma (newly diagnosed/recurrent), **Optune Lua** for malignant pleural mesothelioma and certain NSCLC settings, and—following a major milestone—**Optune Pax**, FDA-approved on Feb 12, 2026 for locally advanced pancreatic cancer (first new FDA-approved treatment for this indication in ~30 years per the report). Novocure monetizes via a recurring monthly service model: the field generator is paired with disposable arrays replaced multiple times weekly, creating strong revenue visibility while patients stay on therapy. FY2025 preliminary net revenue was **$655.4M (+8%)**, driven by a **12%** rise in active patients to **4,620**. The company is in transition, balancing pipeline-to-commercial launches, a CEO change (Frank Leonard, late 2025), and a material administrative setback: CMS revoked U.S. billing privileges, temporarily impairing revenue recognition from CMS payors.